Colorectal and other GI cancers:

Indications for Floxuridine:

Palliative therapy of GI adenocarcinoma with liver metastases in select patients (see literature).


Continuous arterial infusion 0.1–0.6mg/kg per day. Hepatic artery infusion: 0.4–0.6mg/kg per day. May give until adverse reactions occur; treat as long as response continues. See literature.


Not recommended.


Poor nutritional state. Myelosuppression. Serious infections.


Hospitalize for 1st course. Hepatic or renal dysfunction. History of high-dose pelvic irradiation or alkylation therapy. Monitor blood (esp WBC, platelets). Discontinue for myocardial ischemia, stomatitis or esophagopharyngitis, WBC <3500 or rapidly falling, intractable vomiting, GI ulcer/bleeding, diarrhea, platelets <100000, hemorrhage. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Pharmacologic Class:


Adverse Reactions:

GI upset, enteritis, stomatitis, localized erythema, myelosuppression, liver dysfunction, GI bleeding/ulcer, duodenitis, gastroenteritis, glossitis, pharyngitis, intra- and extrahepatic biliary sclerosis, acalculous cholecystitis, alopecia, dermatitis, myocardial ischemia, fever, malaise; lab abnormalities (eg, anemia, leukopenia, thrombocytopenia, abnormal PT, total proteins, ESR, ALT/SGOT, bilirubin, lactic dehydrogenase); procedural complications (eg, arterial aneurysm, ischemia, thrombotic events, fibromyositis, thrombophlebitis, hepatic necrosis, abscess).


Formerly known under the brand name FUDR.

How Supplied:

Contact supplier.